文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局部前列腺癌两分次立体定向放疗联合直肠周围间隔后的急性毒性与早期前列腺特异性抗原反应:SABR-Dual试验初步报告

Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing-Initial Report of the SABR-Dual Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-07-11

SABR-Dual是一项含I期安全性队列的III期试验,评估两分次立体定向放疗联合直肠周围间隔及可选MRI靶区加量治疗局部前列腺癌。I期非随机队列20例患者中,3个月尿失禁、排尿梗阻、肠道、性功能和激素领域微小临床重要变化率分别为5%、30%、10%、20%和25%,2级泌尿和肠道毒性分别为10%和0%,无≥3级毒性,末次随访PSA平均下降70.4%。

要点

  • 两分次前列腺SABR联合直肠周围间隔的2级泌尿毒性为10%,肠道毒性为0%,无≥3级毒性。
  • 3个月尿失禁、排尿梗阻、肠道、性功能和激素领域微小临床重要变化率分别为5%、30%、10%、20%和25%。
  • 末次随访PSA平均下降70.4%±17.7%,国际前列腺症状评分平均增加1±5.4。

核心结论

  • 使用直肠周围间隔的两分次前列腺SABR方案可作为超低分次剂量递增的安全方法,急性毒性轻微。
  • SABR-Dual III期随机部分正在研究更长期结局及与标准5分次SABR的直接比较。

研究设计与样本

  • SABR-Dual为III期试验,包含I期安全性队列,本报告为I期非随机队列的初步报告。
  • 入组条件为低危或预后良好中危前列腺腺癌,腺体体积<80 cc。
  • 所有患者均在模拟定位(CT和3特斯拉T2 MRI)前接受不透射线水凝胶间隔和基准标记置入。
  • 临床靶区包括整个前列腺,预后良好中危患者还包括1-2 cm精囊;计划靶区外扩2 mm。
  • 处方剂量为计划靶区-前列腺27 Gy、计划靶区-精囊23 Gy,可选对MRI定义的优势病灶同步加量至30 Gy。

主要发现

  • I期队列20例患者中,95%为预后良好中危疾病,50%接受同步加量。
  • 中位随访8个月时,3个月微小临床重要变化发生率:尿失禁1/20(5%)、排尿梗阻6/20(30%)、肠道2/20(10%)、性功能4/20(20%)、激素领域5/20(25%)。
  • 国际前列腺症状评分平均增加1±5.4,男性性健康量表评分平均下降1.8±6.5。
  • 2级泌尿毒性和肠道毒性发生率分别为10%和0%,无≥3级毒性。
  • 末次随访PSA平均下降70.4%±17.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: SABR-Dual is a phase-III trial with an initial phase-I safety cohort, of 2-fraction stereotactic radiotherapy (SABR) with optional magnetic resonance imaging (MRI)-based focal boost, using peri-rectal spacing, for localized prostate cancer. This represents the initial report from the phase-I non-randomized cohort. METHODS AND MATERIALS: Subjects had favorable intermediate risk (FIR) or low risk prostate adenocarcinoma, and gland volume <80 cc. All underwent radiopaque hydrogel spacer and fiducial marker placement before simulation (computed tomography and 3-tesla T2 MRI). The clinical target volume included the entire prostate, and in FIR patients, 1-2 cm of seminal vesicle. A 2-mm expansion was applied for planning target volume (PTV), and a dose of 27 Gy was prescribed to the PTV-prostate, 23 Gy to the PTV-seminal vesicle, with an optional 30 Gy simultaneous boost to an MRI-defined dominant lesion. Primary endpoint was 3-month patient-reported changes in quality of life based on the Expanded Prostate Cancer Index Composite-26, International Prostate Symptom Score, and Sexual Health Inventory for Men questionnaires. Secondary endpoints were 6-month quality of life, acute toxicity (using Common Terminology Criteria for Adverse Events version 5.0) and early Prostate specific antigen (PSA) response. RESULTS: Among the 20 patients in the phase-I cohort, 95% had FIR disease, and 50% received a simultaneous boost. At median follow-up of 8 months, a 3-month minimally clinically important change occurred in 1/20 (5%), 6/20 (30%), 2/20 (10%), 4/20 (20%), and 5/20 (25%) in urinary incontinence, urinary obstructive, bowel, sexual, and hormonal domains. There was a mean increase of 1 ± 5.4 in International Prostate Symptom Score and decrease of 1.8 ± 6.5 in Sexual Health Inventory for Men scores. Rates of grade 2 urinary and bowel toxicity were 10% and 0%, respectively, with no grade ≥3 toxicities. Mean PSA decrease at last follow-up was 70.4% ± 17.7%. CONCLUSION: This generalizable protocol of 2-fraction prostate SABR using peri-rectal spacing is a safe approach for ultra-hypofractionated dose-escalation, with minimal acute toxicity. Longer-term outcomes and direct comparison with standard 5-fraction SABR are being studied in the phase-III randomized portion of SABR-Dual.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Fredman E, Moore A, Icht O, et al. Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing-Initial Report of the SABR-Dual Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 39002849. doi:10.1016/j.ijrobp.2024.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。